Alzheimer's disease laboratory findings

Jump to: navigation, search

Alzheimer's disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Alzheimer's disease from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Social Impact

Family Impact

Alzheimer's disease laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Alzheimer's disease laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Alzheimer's disease laboratory findings

CDC on Alzheimer's disease laboratory findings

Alzheimer's disease laboratory findings in the news

Blogs on Alzheimer's disease laboratory findings

Directions to Hospitals Treating Alzheimer's disease

Risk calculators and risk factors for Alzheimer's disease laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

There are no specific diagnostic laboratory findings associated with Alzheimer's disease. However, laboratory findings are done to rule out other conditions which may mimic Alzheimer's disease symptoms. These include CSF analysisfor 2 and tau protein, 14-3-3 protein, vitamin B12 levels, thyroid hormones, electrolytes, HIV serology, complete blood count, blood glucose, renal function test, liver function test, and urine screen for drug abuse.

Laboratory Findings

There are no specific diagnostic laboratory findings associated with Alzheimer's disease. However, laboratory findings are done to rule out other conditions which may mimic Alzheimer's disease symptoms. These include:[1][2][3][4][5][6][7][8]

References

  1. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001). "Current concepts in mild cognitive impairment". Arch. Neurol. 58 (12): 1985–92. PMID 11735772.
  2. Ritchie C, Smailagic N, Noel-Storr AH, Takwoingi Y, Flicker L, Mason SE, McShane R (2014). "Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)". Cochrane Database Syst Rev (6): CD008782. doi:10.1002/14651858.CD008782.pub4. PMID 24913723.
  3. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Bürger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009). "Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study". Lancet Neurol. 8 (7): 619–27. doi:10.1016/S1474-4422(09)70139-5. PMID 19523877.
  4. Ritchie C, Smailagic N, Noel-Storr AH, Ukoumunne O, Ladds EC, Martin S (2017). "CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)". Cochrane Database Syst Rev. 3: CD010803. doi:10.1002/14651858.CD010803.pub2. PMID 28328043.
  5. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, Foster NL, Petersen RC, Weiner MW, Price JC, Mathis CA (2009). "Relationships between biomarkers in aging and dementia". Neurology. 73 (15): 1193–9. doi:10.1212/WNL.0b013e3181bc010c. PMC 2764726. PMID 19822868.
  6. Jeste DV, Dolder CR, Nayak GV, Salzman C (2005). "Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature". Harv Rev Psychiatry. 13 (6): 340–51. doi:10.1080/10673220500433247. PMID 16373328.
  7. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Reiman PE, Zehntner SP, Skovronsky DM (2011). "Use of florbetapir-PET for imaging beta-amyloid pathology". JAMA. 305 (3): 275–83. doi:10.1001/jama.2010.2008. PMID 21245183.
  8. Neugroschl, Judith; Wang, Sophia (2011). "Alzheimer's Disease: Diagnosis and Treatment Across the Spectrum of Disease Severity". Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine. 78 (4): 596–612. doi:10.1002/msj.20279. ISSN 0027-2507.

Linked-in.jpg